Cbz-TAP-Boc | 796865-54-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Cbz-TAP-Boc
• 英文别名: benzyl N-[2-[2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]ethoxy]ethyl]carbamate
• CAS: 796865-54-8
• 化学式: C₁₉H₃₀N₂O₆
• 分子量: 382.457
• InChiKey: SKDRJSTWNAFXKD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  27
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  95.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Cbz-TAP-Boc 在 5%-palladium/activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 16.0h， 生成 2-(2-(2-氨基乙氧基)乙氧基)乙基氨基甲酸叔丁酯
  参考文献：
  名称：

  WO2006/133144

  摘要：

  公开号：
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 CBZNH-二聚乙二醇-氨基 以 正己烷 为溶剂， 生成 Cbz-TAP-Boc
  参考文献：
  名称：

  WO2006/133144

  摘要：

  公开号：

文献信息

• Novel peptides that bind to the erythropoietin receptor
  申请人：Holmes P. Christopher

  公开号：US20070027074A1

  公开（公告）日：2007-02-01

  The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
• Novel spacer moiety for poly (ethylene glycol) modified peptide based compounds
  申请人：Holmes P. Christopher

  公开号：US20070032408A1

  公开（公告）日：2007-02-08

  The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure: —NH—(CH 2 ) α —[O—(CH 2 ) β ] γ —O δ —(CH 2 ) ε —Y— wherein α, β, γ, δ, and ε are each integers whose values are independently selected.
• Erythropoietin receptor peptide formulations and uses
  申请人：Duliege Anne-Marie

  公开号：US20070104704A1

  公开（公告）日：2007-05-10

  The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
• ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES
  申请人：Duliege Anne-Marie

  公开号：US20080081783A1

  公开（公告）日：2008-04-03

  The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
• NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
  申请人：Holmes Christopher P.

  公开号：US20090048166A1

  公开（公告）日：2009-02-19

  The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.